U.S. Biotech Industry Analysis
UpdatedJun 27, 2024
DataAggregated Company Financials
Companies565
- 7D1.0%
- 3M-3.4%
- 1Y10.7%
- YTD1.6%
Over the last 7 days, the Biotech industry has remained flat, although notably Alnylam Pharmaceuticals gained 57%. As for the the longer term, the industry is up 11% over the past 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 28 Jun 2024 | US$1.2t | US$164.4b | -US$27,986,453,486.34 | 27.7x | -41.4x | 7x |
| Sun, 26 May 2024 | US$1.1t | US$164.6b | -US$26,653,350,594.72 | 23.8x | -42.2x | 6.8x |
| Tue, 23 Apr 2024 | US$1.1t | US$164.2b | -US$23,311,155,066.52 | 20.4x | -45.9x | 6.5x |
| Thu, 21 Mar 2024 | US$1.2t | US$164.4b | -US$23,861,120,065.01 | 21.1x | -48.9x | 7.1x |
| Sat, 17 Feb 2024 | US$1.2t | US$169.1b | -US$20,461,379,458.58 | 15.7x | -57.1x | 6.9x |
| Mon, 15 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,556,941.00 | 18.8x | -63.9x | 7x |
| Wed, 13 Dec 2023 | US$1.3t | US$204.6b | -US$22,084,753,624.00 | 19x | -59.4x | 6.4x |
| Fri, 10 Nov 2023 | US$1.2t | US$204.3b | -US$22,786,529,302.00 | 18.9x | -54.1x | 6x |
| Sun, 08 Oct 2023 | US$1.3t | US$207.4b | -US$13,060,168,797.00 | 17.2x | -96.3x | 6.1x |
| Tue, 05 Sep 2023 | US$1.3t | US$207.5b | -US$12,454,516,459.00 | 18.4x | -103.9x | 6.2x |
| Thu, 03 Aug 2023 | US$1.1t | US$187.2b | -US$14,216,380,818.00 | 13.7x | -79.9x | 6.1x |
| Sat, 01 Jul 2023 | US$1.1t | US$186.2b | -US$16,042,400,813.00 | 13.7x | -70x | 6x |
| Mon, 29 May 2023 | US$1.1t | US$185.9b | -US$16,045,777,796.00 | 11.2x | -69.9x | 6x |
| Wed, 26 Apr 2023 | US$1.2t | US$198.4b | -US$3,227,872,728.00 | 13.1x | -364.9x | 5.9x |
| Fri, 24 Mar 2023 | US$1.1t | US$199.5b | -US$3,534,604,837.00 | 12.6x | -316.2x | 5.6x |
| Sun, 19 Feb 2023 | US$1.2t | US$202.6b | -US$64,851,937.00 | 16.5x | -17785.7x | 5.7x |
| Tue, 17 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.9x | 5.8x |
| Thu, 15 Dec 2022 | US$1.2t | US$203.0b | US$1.5b | 14.7x | 771.2x | 5.8x |
| Sat, 12 Nov 2022 | US$1.1t | US$201.0b | US$2.5b | 14.6x | 444x | 5.5x |
| Mon, 10 Oct 2022 | US$1.0t | US$206.1b | US$5.4b | 14.9x | 190.4x | 5x |
| Wed, 07 Sep 2022 | US$1.0t | US$206.1b | US$6.0b | 14.5x | 169.1x | 5x |
| Fri, 05 Aug 2022 | US$1.1t | US$210.6b | US$7.6b | 16.9x | 145.6x | 5.2x |
| Sun, 03 Jul 2022 | US$1.1t | US$212.1b | US$11.0b | 15.8x | 95.4x | 5x |
| Tue, 31 May 2022 | US$1.0t | US$212.8b | US$11.3b | 15.5x | 91x | 4.8x |
| Thu, 28 Apr 2022 | US$1.2t | US$226.2b | US$14.4b | 17x | 82.5x | 5.2x |
| Sat, 26 Mar 2022 | US$1.3t | US$221.9b | US$11.5b | 18.7x | 110.3x | 5.7x |
| Mon, 21 Feb 2022 | US$1.2t | US$216.5b | US$5.6b | 21.8x | 216.7x | 5.6x |
| Wed, 19 Jan 2022 | US$1.3t | US$212.0b | US$2.5b | 23.5x | 519.8x | 6x |
| Fri, 17 Dec 2021 | US$1.4t | US$211.9b | US$3.1b | 25.7x | 454.8x | 6.7x |
| Sun, 14 Nov 2021 | US$1.5t | US$212.2b | US$3.9b | 27.1x | 377.5x | 6.9x |
| Tue, 12 Oct 2021 | US$1.5t | US$196.3b | -US$2,597,169,128.00 | 23.3x | -558.9x | 7.4x |
| Thu, 09 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 21.3x | -697.8x | 8.1x |
| Sat, 07 Aug 2021 | US$1.6t | US$197.0b | -US$1,525,228,785.58 | 23.2x | -1033.1x | 8x |
Price to Earnings Ratio
-1810.8x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.15% | |
| Healthcare | 0.40% | |
| Biotech | 0.96% | |
| Biotech | 0.96% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | US$247.00 | 56.9% +US$11.3b | 29.3% | PS15.6x | |
| SRPT Sarepta Therapeutics | US$157.96 | 27.9% +US$3.3b | 40.7% | PE883.6x | |
| AMGN Amgen | US$313.69 | 1.2% +US$2.0b | 41.8% | PE44.7x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| GRPH Graphite Bio | US$22.26 | 539.7% +US$1.1b | 861.6% | PB7.1x |
